Shares of Cybin Inc. (OTCMKTS:CYBN – Get Free Report) dropped 5.7% during trading on Monday . The stock traded as low as $6.20 and last traded at $6.34. Approximately 269,681 shares changed hands during trading, an increase of 3% from the average daily volume of 261,761 shares. The stock had previously closed at $6.72.
Cybin Stock Up 5.9 %
The firm has a market capitalization of $134.45 million, a price-to-earnings ratio of -32.95 and a beta of 0.61. The stock has a 50 day moving average of $8.43 and a 200 day moving average of $9.21.
Cybin Company Profile
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation.
Recommended Stories
- Five stocks we like better than Cybin
- Investing In Automotive Stocks
- Homebuilders in Freefall: Bargain Opportunity or Falling Knife?
- High Flyers: 3 Natural Gas Stocks for March 2022
- The 3 Most Talked About Investments on WallStreetBets Right Now
- How to Effectively Use the MarketBeat Ratings Screener
- Analyst Targets Signal More Growth in CrowdStrike Stock
Receive News & Ratings for Cybin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cybin and related companies with MarketBeat.com's FREE daily email newsletter.
